Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

Area of Science:

• Oncology
• Immunology
• Stem Cell Biology

Background:

• Antibody-based cancer therapies have achieved significant clinical success.
• The cancer stem cell (CSC) model is emerging as crucial for understanding tumor development, drug resistance, and metastasis.
• CSCs share self-renewal and protective characteristics with normal stem cells, contributing to treatment failure.

Purpose of the Study:

• To review recent discoveries in cancer stem cells (CSCs) across major tumor types.
• To highlight potential molecular targets for CSC intervention.
• To discuss antibody-directed CSC therapies and future prospects.

Main Methods:

• Literature review of recent discoveries in CSCs.
• Analysis of potential CSC targets (e.g., CD133, EpCAM/ESA).
• Examination of antibody-directed CSC therapies and indirect strategies (anti-angiogenic, anti-stroma).

Main Results:

• CSCs exhibit self-renewal, resistance to xenobiotics/DNA damage, and express locomotory receptors, explaining therapeutic challenges.
• Specific CSC markers like CD133 and EpCAM/ESA can be targeted for direct intervention.
• Indirect strategies targeting the CSC niche (e.g., anti-angiogenesis) may also prove effective.

Conclusions:

• Targeting cancer stem cells (CSCs) is a promising strategy to improve cancer therapy outcomes.
• Both direct targeting of CSC markers and indirect modulation of their supportive niche warrant further investigation.
• Antibody-directed therapies against CSCs represent an emerging and evolving area with potential for long-term cancer cures.